Biogen Idec Inc (BIIB) News $BIIB
7 Undeniable Reasons to Invest in Health Care
Keith Speights, The Motley Fool - Motley Fool - 2 hrs 33 mins ago
You need to be in health care. There are no ifs, ands, or buts about it. I'm not talking about working in the health-care industry (although that's not a bad idea, either). At least part of your investment portfolio needs to be in health care...
'Fast Money' Recap: A Down Day
at The Street - Sat Mar 22, 4:00AM CDT
The trading panel discussed how investors are rotating out of high-growth stocks and into stocks like Microsoft and Cisco.
Why Symantec Corporation, Biogen Idec, and Alexion Pharmaceuticals Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Fri Mar 21, 6:39PM CDT
The S&P 500 Index hit all-time highs today. Then it steadily declined for the remainder of the day, driven by a slumping health-care sector. With Symantec Corporation being the lone exception, two of the three biggest losers in the stock...
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
Biotechs, Software, Generics Pace U.S. Stocks Lower
at Investor's Business Daily - Fri Mar 21, 4:04PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower. All but two of the top 10 stocks within the IBD 50 also fell. The Nasdaq composite fell nearly 1%. That shaved the index's...
After Yesterday's Decline of 8.22%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $313.08 to a high of $355.00. Yesterday, the shares fell 8.2%, which took the trading range below the 3-day low of $344.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 8.22% Yesterday
Comtex SmarTrend(R) - Fri Mar 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $313.08 to a high of $355.00. Yesterday, the shares fell 8.2%, which took the trading range below the 3-day low of $344.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
U.S. Stocks Lose Gains, Biotechs Get Hammered
at Investor's Business Daily - Fri Mar 21, 3:26PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower Friday. The Nasdaq composite fell nearly 1%. That shaved the index's weekly advance to less than 0.8%. The S&P 500's 0.6%...
Why Biogen Idec (BIIB) Is Down Today
at The Street - Fri Mar 21, 1:30PM CDT
Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day. The drop comes despite news that Health Canada has approved Biogen...
Use Pyramiding Into A Full Position To Reduce Risk
at Investor's Business Daily - Fri Mar 21, 1:28PM CDT
Jumping into a crystal-clear pool can be a lot of fun. But it's no fun if that water is icy cold. It's best to test the water before fully committing, which is also a wise thing to do in investing. This is essentially the idea behind pyramiding, or...
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Biogen Idec (BIIB) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Mar 21, 11:23AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Nasdaq Back Above Water; Green Plains Jumps
at Investor's Business Daily - Fri Mar 21, 10:54AM CDT
Stocks were higher in unison once again near Friday's halftime after trading mixed earlier. The Dow Jones industrial average rose 0.7%, while the S&P 500 climbed 0.6%. After falling as much as 0.6% earlier, the Nasdaq has turned fractionally higher....
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Business Wire - Fri Mar 21, 7:00AM CDT
Today Biogen Idec (NASDAQ: BIIB) announced that Health Canada has approved ALPROLIX(TM) [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic (protective) infusions starting at once weekly or once every 10-14 days.
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
Pharmacyclics target raised
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Nomura raised its price target on the biotech to 188 from 166 and raised its price target after a survey found Pharmacyclic's (PCYC) Imbruvica preformed better than Gilead's (GILD) idelalisib for treating chronic lymphocytic leukemia. Idelalisib is...
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Biogen Entry to S&P 100 Puts OEF in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Mar 20, 1:00PM CDT
Shares of Biogen are climbing up after announcement of its inclusion to S&P 100 index.
7 Undeniable Reasons to Invest in Health Care
Keith Speights, The Motley Fool - Motley Fool - 2 hrs 33 mins ago
You need to be in health care. There are no ifs, ands, or buts about it. I'm not talking about working in the health-care industry (although that's not a bad idea, either). At least part of your investment portfolio needs to be in health care...
'Fast Money' Recap: A Down Day
at The Street - Sat Mar 22, 4:00AM CDT
The trading panel discussed how investors are rotating out of high-growth stocks and into stocks like Microsoft and Cisco.
Why Symantec Corporation, Biogen Idec, and Alexion Pharmaceuticals Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Fri Mar 21, 6:39PM CDT
The S&P 500 Index hit all-time highs today. Then it steadily declined for the remainder of the day, driven by a slumping health-care sector. With Symantec Corporation being the lone exception, two of the three biggest losers in the stock...
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
Biotechs, Software, Generics Pace U.S. Stocks Lower
at Investor's Business Daily - Fri Mar 21, 4:04PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower. All but two of the top 10 stocks within the IBD 50 also fell. The Nasdaq composite fell nearly 1%. That shaved the index's...
After Yesterday's Decline of 8.22%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $313.08 to a high of $355.00. Yesterday, the shares fell 8.2%, which took the trading range below the 3-day low of $344.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 8.22% Yesterday
Comtex SmarTrend(R) - Fri Mar 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $313.08 to a high of $355.00. Yesterday, the shares fell 8.2%, which took the trading range below the 3-day low of $344.72 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
U.S. Stocks Lose Gains, Biotechs Get Hammered
at Investor's Business Daily - Fri Mar 21, 3:26PM CDT
Stocks lost initial gains as a summary sell-off of biotech and ethical drug names punched the Nasdaq composite sharply lower Friday. The Nasdaq composite fell nearly 1%. That shaved the index's weekly advance to less than 0.8%. The S&P 500's 0.6%...
Why Biogen Idec (BIIB) Is Down Today
at The Street - Fri Mar 21, 1:30PM CDT
Biogen Idec (BIIB) dropped on Friday as the biotech sector sagged amid controversy tied to Gilead Sciences' (GILD) hepatitis C drug Sovaldi, which has been priced at $1,000 a day. The drop comes despite news that Health Canada has approved Biogen...
Use Pyramiding Into A Full Position To Reduce Risk
at Investor's Business Daily - Fri Mar 21, 1:28PM CDT
Jumping into a crystal-clear pool can be a lot of fun. But it's no fun if that water is icy cold. It's best to test the water before fully committing, which is also a wise thing to do in investing. This is essentially the idea behind pyramiding, or...
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Biogen Idec (BIIB) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Mar 21, 11:23AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Nasdaq Back Above Water; Green Plains Jumps
at Investor's Business Daily - Fri Mar 21, 10:54AM CDT
Stocks were higher in unison once again near Friday's halftime after trading mixed earlier. The Dow Jones industrial average rose 0.7%, while the S&P 500 climbed 0.6%. After falling as much as 0.6% earlier, the Nasdaq has turned fractionally higher....
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Business Wire - Fri Mar 21, 7:00AM CDT
Today Biogen Idec (NASDAQ: BIIB) announced that Health Canada has approved ALPROLIX(TM) [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic (protective) infusions starting at once weekly or once every 10-14 days.
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
Pharmacyclics target raised
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Nomura raised its price target on the biotech to 188 from 166 and raised its price target after a survey found Pharmacyclic's (PCYC) Imbruvica preformed better than Gilead's (GILD) idelalisib for treating chronic lymphocytic leukemia. Idelalisib is...
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Biogen Entry to S&P 100 Puts OEF in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Mar 20, 1:00PM CDT
Shares of Biogen are climbing up after announcement of its inclusion to S&P 100 index.
